RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Acceptance of Naltrexone by Pregnant Women Enrolled in Comprehensive Drug Addiction Treatment
An Initial Survey
Jones, H. (2012). Acceptance of Naltrexone by Pregnant Women Enrolled in Comprehensive Drug Addiction Treatment: An Initial Survey. American Journal on Addictions, 21(3), 199-201. https://doi.org/10.1111/j.1521-0391.2012.00229.x
This paper reports the results of an initial survey regarding the potential interest in naltrexone treatment by pregnant women enrolled in comprehensive treatment for substance use disorders. Pregnant women (N = 112) were asked about their interest in taking either an oral or long-acting injectable medication that would stop heroin and/or alcohol use, leave them clear-headed, and without neonatal withdrawal. Results indicate strong interest among pregnant women in antagonist treatment, in either form, with clear interest in learning more about naltrexone. Findings lend support for patient's acceptance of a clinical trial of antagonist treatment in this population. (Am J Addict 2012;21:199201)
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.